Bayer AG

Bayer Reports 9% Year-over-Year Increase in Operating Profit for Q1

Bayer reports Q1 sales of 13.41 billion euros

Bayer's Q1 Adjusted EBITDA Exceeds Expectations at 4.5 Billion Euros

Bayer Granted Priority Review for FXIa Inhibitor

Multiple Companies Announce Major Mergers and Acquisitions

Bayer Acquires Perfuse Therapeutics to Boost Ophthalmology Product Line

NMPA Grants Conditional Approval for Bayer's Innovative Drug Selpercatinib

AskBio Completes AB-1002 Phase II Clinical Trial Participant Enrollment

DKSH and Bayer Thailand Expand Partnership for Endometriosis Drug Commercialization

Bayer and Charite Hospital Collaborate to Establish Berlin Health Innovation Zone

Inclusive Capital Partners Plans to Sell Bayer Shares

Bayer Obtains Approval for Low-dose MRI Contrast Agent in Japan

UBS Raises Bayer's Rating to 'Buy' with a Target Price of €52

Bayer Projects 2026 Revenue of 45-47 Billion Euros

Bayer Announces Significant Efficacy in PEACE-3 Clinical Trial

UBS Raises Bayer's Target Price to 48 Euros

Monsanto Reaches Roundup™ Class Settlement Agreement

Goldman Sachs Reduces Voting Rights in Bayer (ADR) to 5.27%

Bayer to Present asundexian Clinical Trial Results at International Stroke Conference

Bayer Receives Breakthrough Therapy Designation for Sevabernib from FDA and CDE

BAYN

BAYRY

SBIO

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Bayer

Health Care Select Sector SPDR

iShares US Pharma

VanEck Biotech ETF

VG Health

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Nasdaq

Bayer Aktiengesellschaft

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack | BAYRY Stock News

StockTitan

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack | BAYRY Stock News

The U.S. FDA has granted Priority Review status to Bayer's HYRNUO® (sevabertinib) for first-line treatment of HER2-mutated non-small cell lung cancer (NSCLC) in patients with no prior therapy. This decision is based on preliminary results from the ongoing Phase I/II SOHO-01 trial. Bayer aims to address the needs of this patient population and is committed to further investigating HYRNUO's potential as a treatment option.

Proshares Ultra Nasdaq Biotech

U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer | BAYRY Stock News

Bayer Aktiengesellschaft's Crop Science division is on track with its five-year plan focused on cost savings and product launches. Executives announced over EUR 1 billion in savings and projected EUR 3.5 billion in revenue growth. The company aims for core sales growth of 1% to 4% and margin expansion by 2026. Bayer plans to launch several biotech traits and has seen strong sales momentum from recent corn hybrids. However, uncertainties from geopolitical events may impact fertilizer costs and farmer purchasing decisions.

Market Beat

Bank of Montreal

Bayer Aktiengesellschaft Backs Crop Science Targets as Seed Pipeline Gains Momentum

Bayer AG(BAYN.DE)

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack | BAYRY Stock News

U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer | BAYRY Stock News

Bayer Aktiengesellschaft Backs Crop Science Targets as Seed Pipeline Gains Momentum